Dasatinib CA180226
Clinical study to determine whether the drug dasatinib is safe and effective in children and adolescents with chronic myeloid leukemia.
Published results
Summary
Dasatinib provides good results in children with chronic myeloid leukemia
Researchers have evaluated the effectiveness of the drug dasatinib in children with chronic myeloid leukemia (CML), a form of blood cancer. The results show that dasatinib produces a strong response to treatment in many children. Children also generally tolerate the drug well. Dasatinib has now been approved for use in children with CML in Europe and the United States.
Every year, a small number of children in the Netherlands are diagnosed with CML. This is a type of blood cancer in which certain white blood cells are abnormal and continue to replicate. Treatment involves a class of drugs called tyrosine kinase inhibitors (TKIs). These drugs block the replication of the abnormal white blood cells.
Until recently, imatinib was the only TKI targeting BCR-ABL1 that was approved for children with CML. However, about 30% of children had to stop imatinib due to resistance or side effects.
What was studied?
Researchers wanted to know whether dasatinib is an effective treatment for children with CML. Dasatinib is a drug from the TKI class. They investigated how well the drug works and how well children tolerate the treatment.
A total of 113 children participated in the international phase 2 trial. Of these, 84 children had recently been diagnosed with CML. The other 29 children could no longer take imatinib because the drug was no longer effective or caused too many side effects. All children received dasatinib.
What are the results?
The results show that dasatinib works quickly and produces a strong response to treatment in many children (see table). As early as three months, a complete response was observed in 35–41% of the children. After two years, the number of abnormal blood cells had decreased significantly in 90–95% of the children (major cytogenetic response). In 83–94% of the children, no abnormal blood cells were detectable (complete cytogenetic response). In 55–70% of the children, no abnormalities were detectable at the molecular level either (major molecular response).
Cohort | n | 3 months | 6 months | 12 months | 24 months |
Imatinib R/I cohort | 29 | 55% MCyR 41% CCyR |
66% CCyR | 90% MCyR 76% CCyR 41% MMR | 90% MCyR 83% CCyR 55% MMR |
Newly diagnosed cohort | 84 | 35% CCyR | 64% CCyR | 92% CCyR 52% MMR | 95% MCyR 94% CCyR 70% MMR |
R/I=resistant/intolerant; McyR=major cytogenetic response; CcyR=complete cytogenetic response; MMR=major molecular response
In addition, dasatinib appears to be well tolerated by children who were unable to take imatinib due to side effects. Notably, children seem to tolerate dasatinib better than adults. No pleural or pericardial effusions (fluid accumulation around the lungs or the heart) were observed.
Oral suspension
Dasatinib is given once daily and can be taken with food. For children who have difficulty swallowing tablets, an oral suspension has been developed. Because the suspension is absorbed slightly less efficiently by the body, the dose is slightly higher, 72 mg/m² instead of 60 mg/m². The effectiveness of the suspension was comparable to that of the tablets.
What are the next steps?
Based on this phase 2 study and an earlier phase 1 study (Zwaan et al., JCO 2013) both the US and European regulatory authorities have approved dasatinib for use in children with CML.
Longer follow-up is needed to understand the effect of dasatinib on children’s growth and development. Growth delay is a known potential side effect of TKIs. The long-term effects of dasatinib are not yet fully understood.
The researchers also want to investigate further whether children who respond strongly to dasatinib might be able to stop their treatment in the future. At this time, there is still insufficient evidence to determine whether this is safe.
Would you like to read the scientific publication? Please look here: Gore L, et al. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 May 1;36(13):1330-1338.